Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 90 от 222

Набира участници

Brain-Gut Yoga for Functional Dyspepsia and Gastroparesis (FD-GP)

Functional Dyspepsia Gastroparesis

The purpose of this research study is to assess whether using a yoga-based intervention in practice is feasible (possible) and acceptable to patients with Functional Dyspepsia and/or Gastroparesis (FD-GP).

Начало: 18.06.2025 Край: 01.08.2026 Възраст: от 18 г.

United States Wake Forest University Health Sciences NCT06732453

Набира участници Фаза 1

First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults

Respiratory Syncytial Virus Vaccination Human Metapneumovirus Vaccination Parainfluenza Vaccination

This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.

Начало: 18.06.2025 Край: 30.06.2026 Възраст: 65–80 г. Превенция

Australia Clover Biopharmaceuticals AUS Pty NCT06984094

Набира участници Фаза 1

A Study to Evaluate MWN109 Tablets in Healthy Adult Participants

Overweight or Obesity

This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered MWN109 tablets will be assessed in healthy adult participants.

Начало: 18.06.2025 Край: 01.05.2026 Възраст: 18–60 г. Лечение

Australia Shanghai Minwei Biotechnology Co., Ltd NCT06938269

Набира участници Фаза 2

The therapeutic potential of psilocybin in anorexia nervosa in young adults

Anorexia Nervosa

Trial status: Authorised General Anxiety (GAD-2), Patient Health Questionnaire (PHQ-2), Experiences in Close Relationships – (ECR–RS), Life Satisfaction (LS), Positive & Neg Affect (PANAS), Harmony in Life (HILS), Self-compassion (Short SCS), Ten Item Pers Inv (TIPI), AN symptom severity (EDE), Response: A clinically significant improvement in weight and psychological symptoms during the treatment period., Remission: The achievement and maintenance of weight restoration and psychological well-being, with no significant symptoms of anorexia nervosa., Relapse: Defined as a composite outcome during the 6-month follow-up period Incidence of adverse events (AEs) and serious adverse events (SAEs) during the trial period.

Начало: 18.06.2025 Възраст: 18–64 г.

Sweden Region Skane 2024-515163-63-00

Набира участници Фаза 3

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Parkinsons Disease (PD)

Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Начало: 17.06.2025 Край: 01.03.2032 Възраст: 45–75 г. Лечение

Australia, Canada, United States BlueRock Therapeutics NCT06944522

Набира участници Фаза 3

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Homozygous Familial Hypercholesterolemia

This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.

Начало: 17.06.2025 Край: 20.08.2027 Възраст: от 12 г. Лечение

Australia, Canada, Georgia +5 Arrowhead Pharmaceuticals NCT07037771

Набира участници Фаза 4

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Atopic Dermatitis

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

Начало: 16.06.2025 Край: 01.09.2026 Възраст: от 12 г.

Argentina, Brazil, Canada +2 Eli Lilly and Company NCT07006792

Набира участници Фаза 2

A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer

Colorectal Cancer

The aim of Neo-POLEM is to determine the rate of Major Pathological Response (MPR) of \

Начало: 16.06.2025 Край: 31.01.2029 Възраст: от 18 г. Лечение

Australia, United Kingdom University of Southampton NCT06692959

Набира участници

The Combined First Trimester Screening

Preeclampsia (PE) Fetal Growth Restriction Congenital Abnormalities Preterm Labor +3

The project is a national, prospective, multicenter pilot project. The project is focus on setting up the combined first trimester screening in the Czech Republic. The combined first trimester screening is aimed at predicting and detecting the most serious obstetric complications, such as the great obstetrical syndromes (preeclampsia, fetal growth restriction, preterm labor and intrauterine fetal demise "IUFD") and structural congenital defects (morphological and chromosomal). The primary objective of the project is to create a unified methodology for performing and evaluating the combined first trimester screening in connection with the National Health Information System (hereinafter referred to as "NHIS"), which will enable recording, providing analysis and linking recorded clinical parameters with data in the NHIS. The pilot project will also provide data for modeling appropriate mechanisms for reimbursement from public health insurance.

Начало: 15.06.2025 Край: 30.04.2027 Възраст: от 18 г.

Czechia Institute of Health Information and Statistics of the C NCT07015203

Набира участници Фаза 1

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Начало: 15.06.2025 Край: 15.03.2027 Възраст: от 18 г. Лечение

Australia Atridia Pty Ltd. NCT06830850

Набира участници

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

Atrial Fibrillation (AF) Atrial Flutter

The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management. This will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care. Participants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.

Начало: 15.06.2025 Край: 15.06.2028 Възраст: от 18 г.

Canada Ottawa Heart Institute Research Corporation NCT07002450

Набира участници

Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation

Bronchiolitis Bronchiolitis Acute

The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%. According to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context. When the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured "patient pathway", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs. The main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.

Начало: 14.06.2025 Край: 14.03.2027 Възраст: 2–2 г.

France Elsan NCT06842238

Набира участници Фаза 3

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Post-ligation Cardiac Syndrome

The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.

Начало: 13.06.2025 Край: 30.06.2029 Възраст: до 3 г.

United States NICHD Neonatal Research Network NCT06679855

Набира участници Фаза 1

Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Lung Disease

This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.

Начало: 13.06.2025 Край: 01.12.2026 Възраст: 39–69 г. Лечение

Australia SMSbiotech NCT06986070

Набира участници Фаза 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

PIK3CA-Related Overgrowth Spectrum (PROS) Lymphatic Malformations Vascular Malformations PIK3CA Mutation +3

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

Начало: 13.06.2025 Край: 01.10.2031 Възраст: от 2 г. Лечение

Australia, Belgium, Italy +3 Relay Therapeutics, Inc. NCT06789913

Набира участници Фаза 1

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Начало: 12.06.2025 Край: 30.12.2027 Възраст: от 18 г. Лечение

Australia Shenyang Sunshine Pharmaceutical Co., LTD. NCT07016490

Набира участници Фаза 1/2

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Neoplasms, Prostate

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).

Начало: 12.06.2025 Край: 09.08.2028 Възраст: от 18 г.

Canada, France, Japan +2 GlaxoSmithKline NCT06990880

Набира участници

Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours

Brain Tumours

The overall objective of this research is to investigate the clinical characteristics pre- and post-brain tumour resection with a focus on visual verticality disorder, and lateropulsion, including neuroimaging analysis, of a neurosurgical cohort of patients with brain tumours. This prospective observational cohort study will investigate clinical and neuroimaging characteristics and the relationship between lateropulsion and visual verticality disorder in patients pre- and post-brain tumour resection. Patients (aged 18-80 years, with a confirmed diagnosis of brain tumour and a neurosurgical pathway) will be enrolled from the state-wide Neurosurgery Service of Western Australia at Sir Charles Gairdner Hospital.

Начало: 12.06.2025 Край: 30.12.2025 Възраст: 18–80 г.

Australia The University of Western Australia NCT06951659

Набира участници

Brain Network Stimulation for Chronic Low Back Pain.

Chronic Low Back Pain (CLBP)

This study looks at the non-invasive brain stimulation technique in people with chronic low back pain to see: * How effective non-invasive brain stimulation is at improving pain intensity in people with chronic low back pain? * How safe non-invasive brain stimulation is and what side effects there may be? * What study participants think of the study procedures and of the non-invasive brain stimulation as a treatment technique for chronic low back pain. Participants will be assigned to receive either active brain stimulation group or sham stimulation group randomly. Participants will be required to attend a total of twelve treatment sessions (approximately 1-hour each, three sessions per week, for four consecutive weeks). Assessments will be done at baseline (in the week 0), immediately post-completion of the intervention (in the week 5), and at the follow-up of one-month (in the week 8), three-months (in the week 16) and six-months (in the week 28) post-completion of intervention.

Начало: 12.06.2025 Край: 01.01.2028 Възраст: 18–75 г. Лечение

New Zealand University of Otago NCT06902233

Набира участници Фаза 2

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Myelodysplastic Syndrome

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Enasidenib is an enzyme inhibitor that may stop the growth of cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with enasidenib may be effective in treating patients with higher-risk IDH2-mutated MDS.

Начало: 12.06.2025 Край: 01.03.2027 Възраст: от 18 г.

Puerto Rico, United States National Cancer Institute (NCI) NCT06577441

1 … 88 89 90 91 92 … 222